The shadow of generic challenges has consistently loomed around copyright’s famous drug, Viagra, sparking questions about the outlook of similar drug portfolios. While first times saw significant returns, the exclusivity end has allowed the path for cheaper substitutes, possibly diminishing earnings and posing a genuine hazard for stakeholders lo